Quantcast
Last updated on April 19, 2014 at 8:45 EDT

Latest Sulfoxides Stories

2009-11-17 17:14:00

ORLANDO, Fla., Nov. 17 /PRNewswire-USNewswire/ -- Today the FDA notified healthcare professionals of new safety information concerning a drug interaction between clopidogrel, an anti-clotting medication, and omeprazole, a proton pump inhibitor (PPI) used to reduce stomach acid. The FDA notes that they have new data showing that when healthy volunteers received clopidogrel with omeprazole, clopidogrel was less effective in its anti-clotting action than when given without omeprazole. The...

1c50403e7e269b9ad772169abd0aecfd1
2009-11-17 14:37:31

The popular heartburn drugs Prilosec and Nexium can reduce by nearly half the blood thinning effect of the drug Plavix, said officials with the U.S. Food and Drug Administration (FDA) on Tuesday. Plavix, known generically as clopidogrel, is an anti-clotting drug taken by millions of Americans to reduce risks of heart attack and stroke. Nexium and Prilosec belong to a class of heartburn medications known as proton pump inhibitors (PPIs). Regulators said the key ingredient PPIs blocks an...

2009-11-12 07:00:00

CINCINNATI, Nov. 12 /PRNewswire-FirstCall/ -- The National Football League, Prilosec OTC® and Pro-Football Hall-of-Fame Member John Madden announced today the creation of the first annual Madden Most Valuable Protectors Award presented by Prilosec OTC. The award will celebrate the important role linemen play in their team's success and honor the NFL's best offensive linemen based on their 2009 regular season performance. While most attention is typically focused on more...

2009-11-05 10:00:00

FRAZER, Pa., Nov. 5 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with indolent B-cell non-Hodgkin's lymphoma (NHL) whose disease had progressed during or within six months of treatment with rituximab. Results of this study, which supported the FDA approval of TREANDA in this patient population in...

2009-11-04 12:59:00

FRAZER, Pa., Nov. 4 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that its Research and Development Day in New York City, to be held on November 10, 2009, will be webcast live on the investor relations section of its website at http://www.cephalon.com. Cephalon's senior management will review the company's product pipeline and discuss research and development initiatives including its pipeline of biologics from its recent acquisition of Arana Therapeutics. In...

2009-11-02 15:30:00

FRAZER, Pa., Nov. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets [C-IV] significantly improved wakefulness throughout the shift in patients with excessive sleepiness associated with shift work disorder (SWD). NUVIGIL, the longer-lasting isomer of modafinil, is indicated to improve wakefulness in...

2009-10-26 22:50:42

Helicobater pylori, a bacteria implicated in peptic ulcers and gastritis, was eradicated in 95 percent patients who took a 7-day course of combination therapy with levofloxacin, omeprazole, nitazoxanide (Alinia®) and doxycycline (LOAD) compared to eradication in only 80.9 percent of patients on lansoprazole, amoxicillin and clarithromycin (LAC) for seven days. Results of a new study presented at the Annual Scientific Meeting of the American College of Gastroenterology reveal...

2009-10-26 10:09:00

SAN DIEGO, Oct. 26 /PRNewswire/ -- New data being presented at the American College of Gastroenterology (ACG) 2009 Annual Scientific Meeting in San Diego showed that treatment with KAPIDEX(TM) (dexlansoprazole) delayed release capsules over a four-week period resulted in a statistically significant greater percentage of nights without heartburn in subjects with non-erosive gastroesophageal reflux disease (GERD), compared to placebo (p<0.001). In addition, secondary measures showed that...

2009-10-26 07:22:00

FRAZER, Pa. and WELLESLEY, Mass., Oct. 26 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) and BioAssets Development Corporation (BDC), a privately held biopharmaceutical company, today announced that the companies have signed an agreement that will provide Cephalon with an option to acquire BDC. Under the terms of the option agreement, Cephalon will pay BDC an upfront payment of $30 million and, assuming exercise of the option, an additional payment on the closing of the...

2009-10-21 15:05:00

FRAZER, Pa., Oct. 21 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced receipt of a Paragraph IV Certification Notice Letter on October 20, 2009 regarding an Abbreviated New Drug Application (ANDA) submitted to the U.S. Food and Drug Administration (FDA) by Teva Pharmaceuticals USA, Inc. requesting approval to market and sell a generic version of the 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths of NUVIGIL® (armodafinil) Tablets [C-IV]. In the...